Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 4/20 | 0.43 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16050451 | 0.85 | KDM5A (0.47) | PLATKDM5AKDM4DKDM4EALDH1A1 | |
| SCHEMBL16092563 | 0.82 | KDM5B (0.46) | PLATKDM5AJAK2 | |
| SCHEMBL16050392 | 0.80 | KDM5A (0.44) | PLATKDM5A | |
| SCHEMBL16050454 | 0.79 | KDM5A (0.53) | KDM5A | |
| SCHEMBL16092382 | 0.77 | KDM5A (0.48) | PLATKDM5AKDM4DKDM4EALDH1A1 | |
| SCHEMBL16050499 | 0.75 | KDM5A (0.37) | PLATKDM5AKDM4D | |
| SCHEMBL16046338 | 0.73 | PLAT (0.50) | PLATKDM5AKDM4DCHEK1CCNA2 | |
| SCHEMBL16092327 | 0.71 | KDM5A (0.46) | KDM5AROCK2KDM4D | |
| SCHEMBL16534904 | 0.68 | PIK3CA (0.40) | PLATPIK3CAMTOR | |
| SCHEMBL16092319 | 0.67 | PLAT (0.42) | PLATKDM5AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | PLAT 4107/4885KDM5A 1/4885ROCK2 990/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | PLAT 4107/4885KDM5A 1/4885ROCK2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.